Αρχική World News Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously... World News Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC Από Ogkologos - 30 Ιουνίου, 2026 244 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HARMONi-6 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... 24 Μαρτίου, 2025 Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in... 10 Μαΐου, 2024 Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients... 1 Δεκεμβρίου, 2021 Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with... 4 Νοεμβρίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Patients with Early Stage NSCLC Have a Higher TMB in Comparison... Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or...
